PELI Logo
title

References - Clinical Management for Mild Anxiety and Relief of Stress

  1. Australian Bureau of Statistics. National Survey of Mental Health and Wellbeing: summary of results [Internet]. Canberra: Australian Bureau of Statistics; 2007 [cited 2022 May 2]. Available from: https://www.abs.gov.au/statistics/health/mental-health/national-survey-mental-health-and-wellbeing-summary-results/latest-release
  2. Beyond Blue. What causes anxiety? [Internet]. Melbourne: Beyond Blue; 2022 [cited 2022 May 2]. Available from: https://www.beyondblue.org.au/the-facts/anxiety/what-causes-anxiety
  3. Maslach C, Leiter MP. Understanding the burnout experience: recent research and its implications for psychiatry. World Psychiatry. 2016 Jun;15(2):103-111. DOI: 10.1002/wps.20311
  4. Australian Bureau of Statistics. First insights from the National Study of Mental Health and Wellbeing, 2020-21 [Internet]. Canberra: Australian Bureau of Statistics; 2021 [cited 2022 Apr 11]. Available from: https://www.abs.gov.au/articles/first-insights-national-study-mental-health-and-wellbeing-2020-21
  5. Australia’s Mental Health Think Tank. COVID-19 and Australia’s mental health: an overview of academic literature, policy documents, lived experience accounts, media and community reports [Internet]. Sydney: Australia’s Mental Health Think Tank; 2021 [cited 2022 May 2]. Available from: https://apo.org.au/sites/default/files/resource-files/2021-10/apo-nid314410.pdf
  6. Härter MC, Conway KP, Merikangas KR. Associations between anxiety disorders and physical illness. Eur Arch Psychiatry Clin Neurosci. 2003 Dec;253(6):313-320. DOI: 10.1007/s00406-003-0449-y
  7. Pouwer F, Kupper N, Adriaanse MC. Does emotional stress cause type 2 diabetes mellitus? A review from the European Depression in Diabetes (EDID) Research Consortium. Discov Med. 2010 Feb;9(45):112-118.
  8. Stanton R, Rosenbaum S, Rebar A, Happell B. Prevalence of chronic health conditions in Australian adults with depression and/or anxiety. Issues Ment Health Nurs. 2019 Oct;40(10):902-907. DOI: 10.1080/01612840.2019.1613701
  9. Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol Bull. 2004 Jul;130(4):601-630. DOI: 10.1037/0033-2909.130.4.601
  10. Romm A, Hardy ML, Mills S. Kava kava. In: Aviva Romm, editor. Botanical medicine for women’s health. St Louis: Churchill Livingstone; 2010. 694 p.
  11. Natural Medicines Database [Internet]. Denver CO: TRC Healthcare; 2021. Kava; 2021 Jan [cited 2022 May 2]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=872
  12. Alam N, Hossain M, Khalil MI, Moniruzzaman M, Sulaiman SA, Gan SH. Recent advances in elucidating the biological properties of Withania somnifera and its potential role in health benefits. Phytochem Rev. 2012;11:97-112. DOI 10.1007/s11101-011-9221-5
  13. Natural Medicines Database [Internet]. Denver CO: TRC Healthcare; 2022. Ashwagandha; 2022 Mar [cited 2022 Jun 17]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=953
  14. LiverTox. Kava kava [Internet]. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases; 2018 [cited 2022 Jul 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548637/
  15. Ostermayer D. News: kava, popular as alcohol alternative, may cause toxicity. Emergency Medicine News. 2016 Jan;38(1B). DOI: 10.1097/01.EEM.0000480650.58366.f1
  16. Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry. 1995 May;58(5):639-640. DOI: 10.1136/jnnp.58.5.639
  17. Mudd TW, Guddati AK. Management of hepatotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 2021;11(7):3461-3474.
  18. West SG. Methotrexate hepatotoxicity. Rheum Dis Clin North Am. 1997 Nov;23(4):883-915. DOI: 10.1016/s0889-857x(05)70365-3
  19. Sriperumbuduri S, Umar MS, Lajoie-Starkell G, Fairhead TR, Hiremath S. Ashwagandha and kidney transplant rejection. Kidney Int Rep. 2020 Dec;5(12):2375-2378. DOI: 10.1016/j.ekir.2020.09.024
  20. Davis L, Kuttan G. Suppressive effect of cyclophosphamide-induced toxicity by Withania somnifera extract in mice. J Ethnopharmacol. 1998 Oct;62(3):209-214. DOI: 10.1016/s0378-8741(98)00039-7
  21. Beyond Blue. Medical treatments for anxiety [Internet]. Melbourne: Beyond Blue; 2022 [cited 2022 May 2]. Available from: https://www.beyondblue.org.au/the-facts/anxiety/treatments-for-anxiety/medical-treatments-for-anxiety
  22. Gomez AF, Hofmann SG. SSRIs and benzodiazepines for general anxiety disorders (GAD) [Internet]. Silver Spring: Anxiety and Depression Association of America; 2020 [cited 2022 Apr 11]. Available from: https://adaa.org/learn-from-us/from-the-experts/blog-posts/consumer/ssris-and-benzodiazepines-general-anxiety
  23. Australian Psychology Society. Anxiety disorders [Internet]. Melbourne: Australian Psychology Society; 2022 [cited 2022 Apr 26]. Available from: https://psychology.org.au/for-the-public/psychology-topics/anxiety
  24. Schneiderman N, Ironson G, Siegel SD. Stress and health: psychological, behavioral, and biological determinants. Annu Rev Clin Psychol. 2005;1:607-628. DOI: 10.1146/annurev.clinpsy.1.102803.144141
  25. Nollet M, Wisden W, Franks NP. Sleep deprivation and stress: a reciprocal relationship. Interface Focus. 2020 Jun;10(3):20190092. DOI: 10.1098/rsfs.2019.0092
  26. Kimura M, Müller-Preuss P, Lu A, Wiesner E, Flachskamm C, Wurst W, et al. Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol Psychiatry. 2010 Feb;15(2):154-165. DOI: 10.1038/mp.2009.46
  27. Steiger A. Sleep and the hypothalamo-pituitary-adrenocortical system. Sleep Med Rev. 2002 Apr;6(2):125-138. DOI: 10.1053/smrv.2001.0159
  28. Mitchell HA, Weinshenker D. Good night and good luck: norepinephrine in sleep pharmacology. Biochem Pharmacol. 2010 Mar;79(6):801-809. DOI: 10.1016/j.bcp.2009.10.004
  29. Dodt C, Breckling U, Derad I, Fehm HL, Born J. Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. Hypertension. 1997 Jul;30(1 Pt 1):71-76. DOI: 10.1161/01.hyp.30.1.71
  30. Fogaça MV, Duman RS. Cortical GABAergic dysfunction in stress and depression: new insights for therapeutic interventions. Front Cell Neurosci. 2019 Mar;13:87. DOI: 10.3389/fncel.2019.00087
  31. Jie F, Yin G, Yang W, Yang M, Gao S, Lv J, et al. Stress in regulation of GABA amygdala system and relevance to neuropsychiatric diseases. Front Neurosci. 2018;12:562. DOI: 10.3389/fnins.2018.0056
  32. Nuss P. Anxiety disorders and GABA neurotransmission: a disturbance of modulation. Neuropsychiatr Dis Treat. 2015;11:165-75. DOI: 10.2147/NDT.S58841
  33. Gottesmann C. GABA mechanisms and sleep. Neuroscience. 2002;111(2):231-239. DOI: 10.1016/s0306-4522(02)00034-9
  34. Liu B, Liu J, Wang M, Zhang Y, Li L. From serotonin to neuroplasticity: evolvement of theories for major depressive disorder. Front Cell Neurosci. 2017 Sep;11:305. DOI: 10.3389/fncel.2017.00305
  35. Natarajan R, Forrester L, Chiaia NL, Yamamoto BK. Chronic-stress-induced behavioral changes associated with subregion-selective serotonin cell death in the dorsal raphe. J Neurosci. 2017 Jun;37(26):6214-6223. DOI: 10.1523/JNEUROSCI.3781-16.2017
  36. Natarajan R, Northrop NA, Yamamoto BK. Protracted effects of chronic stress on serotonin-dependent thermoregulation. Stress. 2015;18(6):668-676. DOI: 10.3109/10253890.2015.1087502
  37. Gordon JA, Hen R. The serotonergic system and anxiety. Neuromolecular Med. 2004;5(1):27-40. DOI: 10.1385/NMM:5:1:027
  38. Portas CM, Bjorvatn B, Ursin R. Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies. Prog Neurobiol. 2000 Jan;60(1):13-35. DOI: 10.1016/s0301-0082(98)00097-5
  39. Jouvet M. Sleep and serotonin: an unfinished story. Neuropsychopharmacology. 1999 Aug;21(2 Suppl):24S-27S. DOI: 10.1016/S0893-133X(99)00009-3
  40. Sleep Foundation. Seattle WA: OneCare Media; 2022. Anxiety and sleep [Internet]; 2022 [cited 2022 Apr 22]. Available from: https://www.sleepfoundation.org/mental-health/anxiety-and-sleep
  41. Kalmbach DA, Anderson JR, Drake CL. The impact of stress on sleep: pathogenic sleep reactivity as a vulnerability to insomnia and circadian disorders. J Sleep Res. 2018 Dec;27(6):e12710. DOI: 10.1111/jsr.12710
  42. Åkerstedt T, Orsini N, Petersen H, Axelsson J, Lekander M, Kecklund G. Predicting sleep quality from stress and prior sleep--a study of day-to-day covariation across six weeks. Sleep Med. 2012 Jun;13(6):674-679. DOI: 10.1016/j.sleep.2011.12.013
  43. Alvaro PK, Roberts RM, Harris JK. The independent relationships between insomnia, depression, subtypes of anxiety, and chronotype during adolescence. Sleep Med. 2014 Aug;15(8):934-941. DOI: 10.1016/j.sleep.2014.03.019
  44. Jonsdottir IH, Sjörs Dahlman A. Mechanisms in endocrinology: endocrine and immunological aspects of burnout: a narrative review. Eur J Endocrinol. 2019 Mar;180(3):R147-R158. DOI: 10.1530/EJE-18-0741
  45. Kakiashvili T, Leszek J, Rutkowski K. The medical perspective on burnout. Int J Occup Med Environ Health. 2013 Jun;26(3):401-412. DOI: 10.2478/s13382-013-0093-3
  46. Allen MJ, Sabir S, Sharma S. GABA receptor [Internet]. Treasure Island: StatPearls; 2022 [cited 2022 May 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526124/
  47. Banerjee N. Neurotransmitters in alcoholism: a review of neurobiological and genetic studies. Indian J Hum Genet. 2014 Jan;20(1):20-31. DOI: 10.4103/0971-6866.132750
  48. Schuckit MA, Mazzanti C, Smith TL, Ahmed U, Radel M, Iwata N, et al. Selective genotyping for the role of 5-HT2A, 5-HT2C, and GABA alpha 6 receptors and the serotonin transporter in the level of response to alcohol: a pilot study. Biol Psychiatry. 1999 Mar;45(5):647-651. DOI: 10.1016/s0006-3223(98)00248-0
  49. Broderick P, Benjamin AB. Caffeine and psychiatric symptoms: a review. J Okla State Med Assoc. 2004 Dec;97(12):538-542.
  50. Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry. 1985 Mar;42(3):233-243. DOI: 10.1001/archpsyc.1985.01790260027003
  51. Magalhães R, Picó-Pérez M, Esteves M, Vieira R, Castanho TC, Amorim L, et al. Habitual coffee drinkers display a distinct pattern of brain functional connectivity. Mol Psychiatry. 2021 Nov;26(11):6589-6598. DOI: 10.1038/s41380-021-01075-4
  52. Pepping J. Kava: Piper methysticum. Am J Health Syst Pharm. 1999 May 15;56(10):957-960. DOI: 10.1093/ajhp/56.10.957
  53. Pedrosa ECGA, Bezerra APC, Da Costa IM, Pinheiro FI, Guzen FP. Neuroprotective profile of Piper methysticum (kava kava) and its effects on the central nervous system: a systematic review. J Pharm Chem Biol Sci. 2020 Jan-Feb;2(1):55-84. DOI: 10.36619/jpcbs.2020.2.56.80
  54. Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins W, et al. The complete German Commission E monographs: therapeutic guide to herbal medicines. Austin: American Botanical Council; 1998. 685 p.
  55. Chua HC, Christensen ET, Hoestgaard-Jensen K, Hartiadi LY, Ramzan I, Jensen AA, et al. Kavain, the major constituent of the anxiolytic kava extract, potentiates GABAA receptors: functional characteristics and molecular mechanism. PLoS One. 2016;11(6):e0157700. DOI: 10.1371/journal.pone.0157700
  56. Boonen G, Häberlein H. Influence of genuine kavapyrone enantiomers on the GABA-A binding site. Planta Med. 1998 Aug;64(6):504-506. DOI: 10.1055/s-2006-957502
  57. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl). 1994 Dec;116(4):469-474. DOI: 10.1007/BF02247480
  58. Prinsloo D, Van Dyk S, Petzer A, Petzer JP. Monoamine oxidase inhibition by kavalactones from kava (Piper methysticum). Planta Med. 2019 Oct;85(14-15):1136-1142. DOI: 10.1055/a-1008-9491
  59. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry. 1998 Sep;31(5):187-192. DOI: 10.1055/s-2007-979325
  60. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry. 1998 Oct;22(7):1105-1120. DOI: 10.1016/s0278-5846(98)00062-1
  61. Seitz U, Schüle A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med. 1997 Dec;63(6):548-549. DOI: 10.1055/s-2006-957761
  62. Walden J, Von Wegerer J, Winter U, Berger M, Grunze H. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 1997 May;21(4):697-706. DOI: 10.1016/s0278-5846(97)00042-0
  63. Chesworth R, Corbit LH. Noradrenergic β-receptor antagonism in the basolateral amygdala impairs reconsolidation, but not extinction, of alcohol self-administration: Intra-BLA propranolol impairs reconsolidation of alcohol self-administration. Neurobiol Learn Mem. 2018 May;151:59-70. DOI: 10.1016/j.nlm.2018.04.009
  64. White AM. What happened? Alcohol, memory blackouts, and the brain. Alcohol Res Health. 2003;27(2):186-196.
  65. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8(1):45-58. DOI: 10.2174/1381612023396654
  66. Sarris J, Scholey A, Schweitzer I, Bousman C, Laporte E, Ng C, et al. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. Hum Psychopharmacol. 2012 May;27(3):262-269. DOI: 10.1002/hup.2216
  67. Thompson R, Ruch W, Hasenöhrl RU. Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava). Hum Psychopharmacol. 2004 Jun;19(4):243-250. DOI: 10.1002/hup.581
  68. Bilia AR, Gallon S, Vincieri FF. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci. 2002 Apr;70(22):2581-2597. DOI: 10.1016/s0024-3205(02)01555-2
  69. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry. 1997 Jan;30(1):1-5. DOI: 10.1055/s-2007-979474
  70. Hu L, Jhoo JW, Ang CY, Dinovi M, Mattia A. Determination of six kavalactones in dietary supplements and selected functional foods containing Piper methysticum by isocratic liquid chromatography with internal standard. J AOAC Int. 2005 Jan-Feb;88(1):16-25.
  71. Garg V, Dhar VJ, Sharma A, Dutt R. Facts about standardization of herbal medicine: a review. Zhong Xi Yi Jie He Xue Bao. 2012 Oct;10(10):1077-1083. DOI: 10.3736/jcim20121002
  72. Currie BJ, Clough AR. Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use. Med J Aust. 2003 May;178(9):421-422. DOI: 10.5694/j.1326-5377.2003.tb05279.x
  73. Coulter D, Tamayo C, Subramaniam S, Ulbricht C, World Health Organization. Assessment of the risk of hepatotoxicity with kava products [Internet]. World Health Organization; 2007 [cited 2022 May 4]. 82 p. Available from: https://apps.who.int/iris/handle/10665/43630
  74. Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl). 2009 Aug;205(3):399-407. DOI: 10.1007/s00213-009-1549-9
  75. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs. 2002;16(11):731-743. DOI: 10.2165/00023210-200216110-00002
  76. Rex A, Morgenstern E, Fink H. Anxiolytic-like effects of kava-kava in the elevated plus maze test--a comparison with diazepam. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jun;26(5):855-860. DOI: 10.1016/s0278-5846(01)00330-x
  77. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev. 2003 Jan;2003(1):CD003383. DOI: 10.1002/14651858.CD003383
  78. Wheatley D. Stress-induced insomnia treated with kava and valerian: singly and in combination. Hum Psychopharmacol. 2001 Jun;16(4):353-356. DOI: 10.1002/hup.299
  79. Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl). 2001 Sep;157(3):277-283. DOI: 10.1007/s002130100792
  80. Singh N, Bhalla M, De Jager P, Gilca M. An overview on ashwagandha: a rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011;8(5 Suppl):208-213. DOI: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252722/
  81. Thomsen M. Phytotherapy desk reference. 5th ed. 2020. 200 p.
  82. Udayakumar R, Kasthurirengan S, Mariashibu TS, Rajesh M, Anbazhagan VR, Kim SC, et al. Hypoglycaemic and hypolipidaemic effects of Withania somnifera root and leaf extracts on alloxan-induced diabetic rats. Int J Mol Sci. 2009 May;10(5):2367-2382. DOI: 10.3390/ijms10052367
  83. Monograph. Withania somnifera. Altern Med Rev. 2004 Jun;9(2):211-214.
  84. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000 Aug;5(4):334-346.
  85. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazón J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules. 2009 Jul;14(7):2373-2393. DOI: 10.3390/molecules14072373
  86. Salve J, Pate S, Debnath K, Langade D. Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus. 2019 Dec;11(12):e6466. DOI: 10.7759/cureus.6466
  87. Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019 Sep;98(37):e17186. DOI: 10.1097/MD.0000000000017186
  88. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012 Jul;34(3):255-262. DOI: 10.4103/0253-7176.106022
  89. Candelario M, Cuellar E, Reyes-Ruiz JM, Darabedian N, Feimeng Z, Miledi R, et al. Direct evidence for GABAergic activity of Withania somnifera on mammalian ionotropic GABAA and GABAρ receptors. J Ethnopharmacol. 2015 Aug;171:264-272. DOI: 10.1016/j.jep.2015.05.058
  90. Speers AB, Cabey KA, Soumyanath A, Wright KM. Effects of Withania somnifera (ashwagandha) on stress and the stress- related neuropsychiatric disorders anxiety, depression, and insomnia. Curr Neuropharmacol. 2021;19(9):1468-1495. DOI: 10.2174/1570159X19666210712151556
  91. Priyanka G, Anil Kumar B, Lakshman M, Manvitha V, Kala Kumar B. Adaptogenic and immunomodulatory activity of ashwagandha root extract: an experimental study in an equine model. Front Vet Sci. 2020;7:541112. DOI: 10.3389/fvets.2020.541112
  92. Bhatnagar M, Sharma D, Salvi M. Neuroprotective effects of Withania somnifera dunal.: a possible mechanism. Neurochem Res. 2009 Nov;34(11):1975-1983. DOI: 10.1007/s11064-009-9987-7
  93. Naß J, Abdelfatah S, Efferth T. Induction of stress resistance and extension of lifespan in Chaenorhabditis elegans serotonin-receptor knockout strains by withanolide A. Phytomedicine. 2021 Apr;84:153482. DOI: 10.1016/j.phymed.2021.153482
  94. Mehta AK, Binkley P, Gandhi SS, Ticku MK. Pharmacological effects of Withania somnifera root extract on GABAA receptor complex. Indian J Med Res. 1991 Aug;94:312-315.
  95. Yogi W, Tsukada M, Sato Y, Izuno T, Inoue T, Tsunokawa Y, et al. Influences of lavender essential oil inhalation on stress responses during short-duration sleep cycles: a pilot study. Healthcare (Basel). 2021 Jul 18;9(7):909. DOI: 10.3390/healthcare9070909
  96. Marciano M, Vizniak NA. Botanical medicine manual. 2nd ed. Vancouver: Professional Health Systems; 2019. 507 p.
  97. Bone K, Mills S. Principles and practice of phytotherapy: modern herbal medicine. 2nd ed. London: Churchill Livingstone; 2013. 1051 p.
  98. Fißler M, Quante A. A case series on the use of Lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety. Complement Ther Med. 2014 Feb;22(1):63-69. DOI: 10.1016/j.ctim.2013.11.008
  99. Fisher C. Materia medica of Western herbs. Nelson: Vitex Medica; 2009. 341 p.
  100. Denner SS. Lavandula angustifolia Miller: English lavender. Holist Nurs Pract. 2009 Jan-Feb;23(1):57-64. DOI: 10.1097/01.HNP.0000343210.56710.fc
  101. Kamalifard M, Farshbaf-Khalili A, Namadian M, Ranjbar Y, Herizchi S. Comparison of the effect of lavender and bitter orange on sleep quality in postmenopausal women: a triple-blind, randomized, controlled clinical trial. Women Health. 2018 Sep;58(8):851-865. DOI: 10.1080/03630242.2017.1353575
  102. Re L, Barocci S, Sonnino S, Mencarelli A, Vivani C, Paolucci G, et al. Linalool modifies the nicotinic receptor-ion channel kinetics at the mouse neuromuscular junction. Pharmacol Res. 2000 Aug;42(2):177-182. DOI: 10.1006/phrs.2000.0671
  103. Höferl M, Krist S, Buchbauer G. Chirality influences the effects of linalool on physiological parameters of stress. Planta Med. 2006 Oct;72(13):1188-1192. DOI: 10.1055/s-2006-947202
  104. Kuroda K, Inoue N, Ito Y, Kubota K, Sugimoto A, Kakuda T, et al. Sedative effects of the jasmine tea odor and (R)-(-)-linalool, one of its major odor components, on autonomic nerve activity and mood states. Eur J Appl Physiol. 2005 Oct;95(2-3):107-114. DOI: 10.1007/s00421-005-1402-8
  105. Aoshima H, Hamamoto K. Potentiation of GABAA receptors expressed in Xenopus oocytes by perfume and phytoncid. Biosci Biotechnol Biochem. 1999 Apr;63(4):743-748. DOI: 10.1271/bbb.63.743
  106. Brum LF, Elisabetsky E, Souza D. Effects of linalool on [(3)H]MK801 and [(3)H] muscimol binding in mouse cortical membranes. Phytother Res. 2001 Aug;15(5):422-425. DOI: 10.1002/ptr.973
  107. Guillemain J, Rousseau A, Delaveau P. [Neurodepressive effects of the essential oil of Lavandula angustifolia Mill]. Ann Pharm Fr. 1989;47(6):337-343.
  108. Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine. 2010 Feb;17(2):94-99. DOI: 10.1016/j.phymed.2009.10.006
  109. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013. 947 p.
  110. Sarris J, Stough C, Bousman CA, Wahid ZT, Murray G, Teschke R, et al. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2013 Oct;33(5):643-648. DOI: 10.1097/JCP.0b013e318291be67
  111. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. Kava-Kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine. 2003;10 Suppl 4:38-49. DOI: 10.1078/1433-187x-00309
  112. Cooley K, Szczurko O, Perri D, Mills EJ, Bernhardt B, Zhou Q, et al. Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974. PLoS One. 2009 Aug;4(8):e6628. DOI: 10.1371/journal.pone.0006628
  113. Gastpar M, Klimm HD. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial. Phytomedicine. 2003 Nov;10(8):631-639. DOI: 10.1078/0944-7113-00369
  114. Kuchta K, Hladikova M, Thomsen M, Nahrstedt A, Schmidt M. Kava (Piper methysticum) extract for the treatment of nervous anxiety, tension and restlessness. Drug Res (Stuttg). 2021 Feb;71(2):83-93. DOI: 10.1055/a-1268-7135
  115. Kalin NH. The critical relationship between anxiety and depression. Am J Psychiatry. 2020 May;177(5):365-367. DOI: 10.1176/appi.ajp.2020.20030305
  116. Martin JL, Sainz-Pardo M, Furukawa TA, Martín-Sánchez E, Seoane T, Galán C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007 Sep;21(7):774-782. DOI: 10.1177/0269881107077355
  117. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65 Suppl 5:7-12.
  118. Gupta GL, Rana AC. Protective effect of Withania somnifera dunal root extract against protracted social isolation induced behavior in rats. Indian J Physiol Pharmacol. 2007 Oct-Dec;51(4):345-353.
  119. Bazrafshan MR, Jokar M, Shokrpour N, Delam H. The effect of lavender herbal tea on the anxiety and depression of the elderly: a randomized clinical trial. Complement Ther Med. 2020 May;50:102393. DOI: 10.1016/j.ctim.2020.102393
  120. Jed Foundation. Understanding anxious feelings [Internet]. New York: Jed Foundation; 2022 [cited 2022 Apr 28]. Available from: https://jedfoundation.org/resource/understanding-anxious-feelings/
  121. MedlinePlus [Internet]. Bethesda, MD: National Library of Medicine; 2022. Stress and your health; 2022 Apr [cited 2022 Apr 28]. Available from: https://medlineplus.gov/ency/article/003211.htm
  122. American Psychology Association. What’s the difference between stress and anxiety? [Internet]. Washington: American Psychology Association; 2022 [cited 2022 Apr 28]. Available from: https://www.apa.org/topics/stress/anxiety-difference
  123. Cropley M, Cave Z, Ellis J, Middleton RW. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res. 2002 Feb;16(1):23-27. DOI: 10.1002/ptr.1002
  124. Sanei R, Chasmi FN. Effect of Lavandula angustifolia extract to prevent test anxiety (a study on students at two time intervals). Entomol Appl Sci Lett. 2018;5(1):1-6.
  125. Shahinfar J, Masroornia M, Vafayi S, Hashemi F, Zera’ati H. Comparison of the effects of lavender and diazepam on the anxiety level of patients before orthopedic surgery. Med Surg Nurs J. 2017;5(3):e67990.
  126. Farshbaf-Khalili A, Kamalifard M, Namadian M. Comparison of the effect of lavender and bitter orange on anxiety in postmenopausal women: a triple-blind, randomized, controlled clinical trial. Complement Ther Clin Pract. 2018 May;31:132-138. DOI: 10.1016/j.ctcp.2018.02.004
  127. Natural Medicines Database [Internet]. Denver CO: TRC Healthcare; 2022. Lavender; 2022 Mar [cited 2022 May 2]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=838
  128. Van Der Hooft CS, Hoekstra A, Winter A, De Smet PAG, Stricker BHC. [Thyrotoxicosis following the use of ashwagandha]. Ned Tijdschr Geneeskd. 2005 Nov;149(47):2637-2638.
  129. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DOI: 10.1038/s41584-020-0372-x
  130. Braun L, Cohen M, Arthur R, Fox G, McEwen B, Oates L, et al. Herbs & natural supplements, volume 2: an evidence-based guide. 4th ed. Sydney: Churchill Livingstone; 2015. 1362 p.
  131. Tharakan A, Shukla H, Benny IR, Tharakan M, George L, Koshy S. Immunomodulatory effect of Withania somnifera (ashwagandha) extract-a randomized, double-blind, placebo controlled trial with an open label extension on healthy participants. J Clin Med. 2021 Aug;10(16):3644. DOI: 10.3390/jcm10163644
  132. Khan MA, Ahmed RS, Chandra N, Arora VK, Ali A. In vivo, extract from Withania somnifera root ameliorates arthritis via regulation of key immune mediators of inflammation in experimental model of arthritis. Antiinflamm Antiallergy Agents Med Chem. 2019;18(1):55-70. DOI: 10.2174/1871523017666181116092934
  133. Kumar G, Srivastava A, Sharma SK, Rao TD, Gupta YK. Efficacy & safety evaluation of Ayurvedic treatment (ashwagandha powder & sidh makardhwaj) in rheumatoid arthritis patients: a pilot prospective study. Indian J Med Res. 2015 Jan;141(1):100-106. DOI: 10.4103/0971-5916.154510
  134. Ghawte SA, Nikhat S, Ahmad J, Mulla G. Withania somnifera L. Dunal a potential herb for the treatment of rheumatoid arthritis. Ann Phytomedicine. 2014;3(1):98-102.
  135. Triantafillidis JK, Triantafyllidi A, Vagianos C, Papalois A. Favorable results from the use of herbal and plant products in inflammatory bowel disease: evidence from experimental animal studies. Ann Gastroenterol. 2016 Jul-Sep;29(3):268-281. DOI: 10.20524/aog.2016.0059
  136. Ke F, Yadav PK, Ju LZ. Herbal medicine in the treatment of ulcerative colitis. Saudi J Gastroenterol. 2012 Jan-Feb;18(1):3-10. DOI: 10.4103/1319-3767.91726
  137. Pawar P, Gilda S, Sharma S, Jagtap S, Paradkar A, Mahadik K, et al. Rectal gel application of Withania somnifera root extract expounds anti-inflammatory and muco-restorative activity in TNBS-induced inflammatory bowel disease. BMC Complement Altern Med. 2011 Apr;11:34. DOI: 10.1186/1472-6882-11-34


logo

Your one stop destination for education and clinical tools, driven by our purpose to inspire people to live better lives through natural healthcare.

Customer Care or Clinical Support

1300 654 336

or visit www.myintegria.com

© 2025, Integria is a registered trademark of Integria Healthcare (Australia) Pty Ltd

Terms of Use | Privacy | Policies